The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the ongoing progress in the race to develop neurodegenerative disease treatments, Biogen and Ionis announced positive Phase 2 results from the CELIA study of diranersen for early Alzheimer's disease. The data demonstrated a robust reduction in tau protein levels, a key biomarker of the disease, alongside meaningful clinical outcomes for patients. Consequently, Biogen plans to advance the drug's development and initiate Phase 3 trials to evaluate its efficacy on a broader scale.
This announcement comes amid intense competition in the biotech sector, as Biogen seeks to solidify its leadership following previous approvals for its drug Leqembi. In comparison to peers, Eli Lilly recently made similar strides with its drug Kisunla, positioning diranersen strategically as a potential therapy targeting tau rather than just amyloid. Per market data, these results reflect cautious optimism in a sector that has experienced sharp volatility linked to clinical trial outcomes over the past year.
Regarding market performance, BIIB stood at $209.03 while IONS closed at $56.75 (close of July 13, 2026). Investors are now monitoring for further updates from the AAIC 2026 conference, in addition to watching the FOMC minutes scheduled for July 8, which could impact risk appetite across the growth and biotech sectors.